Meng Lee
7 Papers
Meng Lee is an academic researcher. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 3, co-authored 7 publications.
Chat about Author
Papers
Association Between Intensity of Low-Density Lipoprotein Cholesterol Reduction With Statin-Based Therapies and Secondary Stroke Prevention
TL;DR: It is suggested that more intensive LDL-C–lowering statin-based therapies might be warranted for patients with ischemic stroke with evidence of atherosclerosis.
Effects of endovascular therapy for mild stroke due to proximal or M2 occlusions: meta-analysis
TL;DR: In this article , the authors conducted a meta-analysis to evaluate the effect of endovascular therapy (EVT) in mild acute ischemic stroke (AIS) due to proximal versus distal occlusions.
17
Efficacy of endovascular therapy for basilar and vertebral artery occlusion: A systematic review and meta-analysis of randomized controlled trials.
TL;DR: In this article , the authors conducted a systematic review and meta-analysis of RCTs comparing endovascular therapy (EVT) vs best medical management (BMM), and found that EVT vs BMM was associated with an increased rate of 90-day ambulation (RR 1.54, 95% CI 1.16-2.05), independence, and a reduced risk of mortality (RR 0.76, 0.65-0.89), but an increased risk of sICH (RR 7.48, 2.27-24).
12
Association Between Magnitude of Differential Blood Pressure Reduction and Secondary Stroke Prevention
TL;DR: In this paper , a meta-analysis and meta-regression of randomized clinical trials evaluates the association of magnitude of differential blood pressure reduction and recurrent stroke in patients with stroke or transient ischemic attack.
Metformin Plus a Low Hypoglycemic Risk Antidiabetic Drug vs. Metformin Monotherapy for Untreated Type 2 Diabetes Mellitus: A Meta-analysis of Randomized Controlled Trials.
TL;DR: In this article , a meta-analysis of randomized controlled trials (RCTs) was conducted to compare the effectiveness of glycemic control and hypoglycemia risk of combination therapy (metformin plus a low hypoglycemic risk antidiabetic drug) vs. standard metformin monotherapy, in patients with untreated type 2 diabetes mellitus (T2DM).
2